Key facts
- This page summarizes James E. Levine's Form 4 filing for Cardiff Oncology, Inc. (CRDF).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 18 Dec 2024, 16:37.
James E. Levine - 16 Dec 2024 Form 4 Insider Report for Cardiff Oncology, Inc. (CRDF)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- CRDF
- Reported as of
- 16 Dec 2024
- Net transaction value
- +$36,726
- SEC form
- 4
- Accepted by SEC
- 18 Dec 2024, 16:37:28 UTC
- Prior SEC filing
- 07 Mar 2024
- Next SEC filing
- 13 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ James Levine
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
James E. Levine filed Form 4 for Cardiff Oncology, Inc. (CRDF) on 18 Dec 2024.
Change
- Previous filing in this sequence was filed on 07 Mar 2024.
- Current net transaction value: +$36,726.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CRDF
transaction
Common Stock
Purchase
- Transaction value
- $9,820
- Shares
- +2,564
- Change %
- +4.3%
- Price
- $3.83
- Shares after
- 62,564
- Date
- 16 Dec 2024
- Ownership
- By Wife
CRDF
transaction
Common Stock
Purchase
- Transaction value
- $14,905
- Shares
- +2,752
- Change %
- +4.4%
- Price
- $5.42
- Shares after
- 65,316
- Date
- 17 Dec 2024
- Ownership
- By Wife
CRDF
transaction
Common Stock
Purchase
- Transaction value
- $12,000
- Shares
- +2,400
- Change %
- +3.7%
- Price
- $5.00
- Shares after
- 67,716
- Date
- 18 Dec 2024
- Ownership
- By Wife
* marks a reported price that did not pass the local price check.